Protein supplementation has shown to improve muscle mass in older adults. However, its effect may be influenced by supplementation dose, frequency and timing. This systematic review aimed to assess the effect of dose, frequency and timing of protein supplementation on muscle mass in older adults. Five databases were systematically searched from inception to 14 March 2023, for randomised controlled trials investigating the effect of protein supplementation on muscle mass in adults aged ≥65 years. Random effects meta-analyses were performed, stratified by population. Subgroups were created for dose (≥30 g, <30 g/day), frequency (once, twice, three times/day) and timing of supplementation (at breakfast, breakfast and lunch, breakfast and dinner, all meals, between meals). Heterogeneity within and between subgroups was assessed using I 2 and Cochran Q statistics respectively. Thirty-eight articles were included describing community-dwelling (28 articles, n=3204, 74.6±3.4 years, 62.8 % female), hospitalised (8 articles, n=590, 77.0±3.7 years, 50.3 % female) and institutionalised populations (2 articles, n=156, 85.7±1.2 years, 71.2 % female). Protein supplementation showed a positive effect on muscle mass in community-dwelling older adults (standardised mean difference 0.116; 95 % confidence interval 0.032–0.200 kg, p=0.007, I 2=15.3 %) but the effect did not differ between subgroups of dose, frequency and timing (Q=0.056, 0.569 and 3.084 respectively, p>0.05). Data including hospitalised and institutionalised populations were limited. Protein supplementation improves muscle mass in community-dwelling older adults, but its dose, frequency or timing does not significantly influence the effect.
MULTIFILE
Introduction: Zygomatic fractures can be diagnosed with either computed tomography (CT) or direct digital radiography (DR). The aim of the present study was to assess the effect of CT dose reduction on the preference for facial CT versus DR for accurate diagnosis of isolated zygomatic fractures. Materials and methods: Eight zygomatic fractures were inflicted on four human cadavers with a free fall impactor technique. The cadavers were scanned using eight CT protocols, which were identical except for a systematic decrease in radiation dose per protocol, and one DR protocol. Single axial CT images were displayed alongside a DR image of the same fracture creating a total of 64 dual images for comparison. A total of 54 observers, including radiologists, radiographers and oral and maxillofacial surgeons, made a forced choice for either CT or DR. Results: Forty out of 54 observers (74%) preferred CT over DR (all with P < 0.05). Preference for CT was maintained even when radiation dose reduced from 147.4 mSv to 46.4 mSv (DR dose was 6.9 mSv). Only a single out of all raters preferred DR (P ¼ 0.0003). The remaining 13 observers had no significant preference. Conclusion: This study demonstrates that preference for axial CT over DR is not affected by substantial (~70%) CT dose reduction for the assessment of zygomatico-orbital fractures.
MULTIFILE
Op verzoek van Jelle Scheurleer: Purpose: To investigate the accuracy of dose calculation on cone beam CT (CBCT) data sets after HU-RED calibration and validation in phantom studies and clinical patients. Material and methods: Calibration of HU-RED curves for kV-CBCT were generated for three clinical protocols (H&N, thorax and pelvis) by using a Gammex RMI phantom with human tissue equivalent inserts and additional perspex blocks to account for patient scatter. Two calibration curves per clinical protocol were defined, one for the Varian Truebeam 2.0 and another for the OBI systems (Varian, Palo Ato). Differences in HU values with respect to the CT-calibration curve were evaluated for all the inserts. Four radiotherapy plans (breast, prostate, H&N and lung) were produced on an anthropomorphic phantom (Alderson) to evaluate dose differences on the kV-CBCT with the new calibration curves with respect to the CT based dose calculation. Dose differences were evaluated according to the D2%, D98% and Dmean metrics extracted from the DVHs of the plans and - evaluation (2%, 1mm) on the three planes at the isocenter for all plans. Clinical evaluation was performed on 5 patients and dose differences were evaluated as in the phantom study.
